Rajasthan's Drug Control Department banned the oxytocin injection TOCIN after a sample failed quality and potency tests.
The ban is critical because oxytocin is used to manage childbirth and prevent postpartum hemorrhage. A failure in potency can lead to ineffective treatment during life-threatening deliveries, increasing the risk of maternal mortality.
Officials targeted TOCIN 5 ml injections manufactured by Jackson Laboratories Pvt Ltd. The department said the ban followed a quality test that revealed the samples contained insufficient oxytocin [1, 2]. Following the discovery, authorities seized 3,500 vials of the drug in the Kota district [1].
The regulatory action comes amid reports of maternal deaths in Kota hospitals. Some reports indicate five deaths occurred [2], while other accounts specify that two women died during C-sections at New Medical College Hospital [3].
Despite the timing of the ban, the Drug Control Department said the drug was not directly linked to those deaths [1, 2]. The department said the seizure and ban were the result of the failed potency standards discovered during testing.
The oxytocin drug is a standard medical intervention used to induce labor or control bleeding after delivery. When the active ingredient is insufficient, the drug cannot perform its primary function, which may leave patients vulnerable during the most critical stages of childbirth.
“Rajasthan's Drug Control Department banned the oxytocin injection TOCIN after a sample failed quality and potency tests.”
This incident highlights the volatility of pharmaceutical quality control in regional Indian healthcare. While officials have decoupled the potency failure from the specific maternal deaths in Kota, the coincidence of sub-standard medication and patient fatalities underscores the danger of 'silent' potency failures, where a drug is present but chemically ineffective, potentially delaying life-saving interventions.
